IART (32) BBNX (36) SGP (41) IRMD (68) ⌘ Pro Terminal →

SI-BONE Inc. (SIBN) — RQD Stock Rating Cockpit

$22.41 +2.66% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

SI-BONE Inc. (SIBN) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.00B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SIBN)Realized 20D OHLCV Swing Band: ±8.7%

RSI-14 MOMENTUMBULLISH MOMENTUM

58.630 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

8.73>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

6 / 99-Pt Accounting

52-WEEK LASER RANGE95% OF RANGE

L: $11$22.41H: $23

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on SIBN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (45)

-10.3% ROIC with 79.6% gross margin and -0.90% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 8.73 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (42)

14/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like SIBN

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SIBN)

✓Walkthrough of SIBN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SIBN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +80.87%▲ ASCENDING CHANNEL

2026-10-30O $22.25H $22.41L $20.95C $22.41VOL 1.25M

RES: $24.09SUP: $18.63SMA50: $19.41SMA200: $16.40

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SIBN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SIBN Butterfly Map → + Track SIBN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +20.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SIBN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SIBN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SIBN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SIBN)

Health Care Rank #380 of 1016 ⚔️ IART vs SIBN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SIBN vs. IART, BBNX, SGP, IRMD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SI-BONE Inc. (SIBN) ranks #380 by composite RQD confidence (48/100, grade D) and #360 by equity capitalization ($1.00B). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with SIBN at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SIBN ACTIVE SI-BONE Inc.	D	48/100	—	79.6%	-10.3%	+2.66%	$1.00B	Benchmark Subject
IART Integra LifeSciences Holdings Corporation	E	32/100	—	50.9%	-35.0%	+4.82%	$998.2M	/iart-vs-sibn →
BBNX Beta Bionics Inc.	D-	36/100	—	55.4%	-22.1%	-1.51%	$955.8M	/bbnx-vs-sibn →
SGP SpyGlass Pharma Inc.	D-	41/100	—	—	-35.0%	-1.06%	$1.09B	/sgp-vs-sibn →
IRMD iRadimed Corporation	C+	68/100	48.8x	76.7%	37.7%	+2.16%	$1.10B	/irmd-vs-sibn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001459839

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SI-BONE Inc. (SIBN) reported GAAP revenue of $200.9M (+20.2% vs. FY2024 revenue of $167.2M , and +44.7% cumulative change since FY2023) , GAAP net income of -$18.9M, operating cash flow of -$675.0K, and free cash flow of -$9.1M (+60.3% YoY). On the balance sheet, SIBN closed FY2025 with $238.6M in total assets against $35.6M in total debt (Altman Z-Score: 8.73, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$200.9M	-$18.9M	-$675.0K	-$9.1M	$238.6M	$35.6M
FY2024 (FY)	2024-12-31	$167.2M	-$30.9M	-$12.4M	-$22.9M	$230.4M	$35.5M
FY2023 (FY)	2023-12-31	$138.9M	-$43.3M	-$18.7M	-$18.7M	—	—

3. SIBN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SIBN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, SI-BONE Inc. (NASDAQ: SIBN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $22.41 (+2.66% 1D, market cap $1.00B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SIBN ranks #380 in composite RQD confidence.

How does SIBN compare to IART and BBNX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), SIBN carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of 79.6%, and ROIC of -10.3%. By comparison, IART (Integra LifeSciences Holdings Corporation) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $998.2M) and BBNX (Beta Bionics Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -22.1%, cap $955.8M). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SIBN?

Per SIBN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001459839), SI-BONE Inc. generated $200.9M in revenue (+20.2% YoY), -$18.9M in net income, and -$9.1M in free cash flow against $238.6M in total assets and $35.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SIBN trading relative to its 50-day, 200-day, and 52-week technical levels?

SIBN last traded at $22.41 (+2.66% on volume of 950,321 shares), positioning the stock +15.46% above its 50-day simple moving average ($19.41) and +36.65% above its 200-day simple moving average ($16.40). Across its 52-week range of $11.48 to $22.95, SIBN sits at the 95.3% percentile with a 14-day RSI of 58.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.7% ($20.46 to $24.36).

SIBN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell SIBN stock right now?

SI-BONE Inc. (SIBN) currently earns a Roarable Rating of D (Sell — SELL) with 48/100 RQD Confidence. Stretched risk/reward at current multiples (-10% return on capital) under elevated 10-year interest-rate pressure.

What is SIBN's 12-month price target and RQD AI Jury consensus?

SIBN's 12-month base price target is $21.4 (range $16.69 to $25.25), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: SIBN RQD Cockpit SIBN 12M Forecast SIBN Earnings & Move SIBN Dividends & DRIP SIBN Insiders & 13F SIBN Whale Options SIBN Profit Sankey SIBN News & Why